Chidamide Tablets is an antineoplastic agent indicated for patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) who have received at least one prior course of systemic chemotherapy, as well as for certain patients with breast cancer.
Precautions for Chidamide Tablets
The following precautions should be noted when taking Chidamide Tablets:
1.Before taking the medication, discuss your personal and family medical history, allergy history, and current medication status with your doctor, and follow the doctor’s guidance to rule out any contraindications to the drug. Read the package insert carefully to learn about the drug’s adverse reactions and other relevant information, so as to avoid serious medication risks.
2.This product has a certain teratogenic effect and may interfere with the normal fetal development; thus, it is contraindicated in pregnant women. Lactating women should discontinue breastfeeding during chidamide treatment. In addition, this product may impair the reproductive capacity of male patients. Therefore, male patients should refrain from making fertility plans during treatment and for 3 months after the end of treatment.
3.Relevant data on the safety and efficacy of this product in pediatric populations are currently lacking, and its use is not recommended for patients under 18 years of age.
4.Patients may experience hematological adverse reactions such as thrombocytopenia, leukopenia and hemoglobin reduction during treatment with Chidamide Tablets. It is recommended that patients undergo a complete blood count (CBC) once a week. In case of severe adverse reactions, symptomatic treatment should be administered and the drug should be temporarily discontinued.
5.This product may cause prolongation of the QTc interval in patients. If a patient has abnormal serum potassium, calcium or magnesium levels detected prior to the first dose, medication should only be initiated after these indicators return to the normal range. During treatment, it is recommended to perform electrocardiogram (ECG) and electrolyte tests every 3 weeks.
6.Monitor for adverse drug reactions during the medication period. Any severe, persistent or progressive adverse reaction must be promptly communicated to the doctor.
